Press Releases April 21, 2026 04:30 PM

Veeco Announces Date for First Quarter 2026 Financial Results and Conference Call

Veeco Instruments announces Q1 2026 earnings release date and conference call details

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
VECO

Veeco Instruments Inc., a leading manufacturer of semiconductor process equipment, plans to release its first quarter 2026 financial results after market close on May 5, 2026, followed by a conference call to discuss the results. The company provided dial-in and webcast information for investors and highlighted the presence of forward-looking statements with associated risks.

Veeco Announces Date for First Quarter 2026 Financial Results and Conference Call
VECO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Veeco will release Q1 2026 financial results on May 5, 2026, after market close.
  • A conference call to review the results will be held at 5:00 PM ET the same day, accessible via phone and webcast.
  • Veeco is a leading supplier of specialized semiconductor manufacturing equipment impacting the semiconductor manufacturing sector.

PLAINVIEW, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) plans to release its first quarter 2026 financial results after the market closes on Tuesday, May 5, 2026. The company will host a conference call to review these results starting at 5:00 PM ET that day.

To join the call, dial 1-877-407-8029 (toll-free) or 1-201-689-8029. Participants may also access a live webcast of the call by visiting Veeco's investor relations website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website beginning at 8:00 PM ET that same evening.

About Veeco
Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco's systems and service offerings, visit www.veeco.com.

To the extent that this news release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include the risks discussed in the Business Description and Management's Discussion and Analysis sections of Veeco's Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K and press releases. Veeco does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.

Veeco Contacts:
Investor Relations: Alex Delacroix | (516) 528-1020 | [email protected]
Media: Brenden Wright | (410) 984-2610 | [email protected]        


Risks

  • Forward-looking statements in the release are subject to risks and uncertainties that could cause actual results to differ materially, notably market and operational risks in the semiconductor equipment industry.
  • Financial performance depends on the volatile semiconductor market demand and macroeconomic conditions.
  • Future events and circumstances could change, and Veeco does not commit to updating forward-looking statements.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026